Royalty Pharma (RPRX) Q3 2024 earnings summary

Executive summary

• Achieved 15% year-over-year growth in Q3 2024 Portfolio and Royalty Receipts, reaching $735 million and $732 million, respectively, with net income surging to $544 million and strong recurring cash inflows.

• Year-to-date capital deployment reached $2.6 billion, with $1.2 billion deployed in Q3, and robust investments in royalties for innovative therapies.

• Repurchased $95 million in shares during Q3, totaling $180 million for the first nine months of 2024.

• Raised full-year 2024 guidance for Portfolio Receipts to $2.75–$2.8 billion and Royalty Receipts growth to 11–13%, driven by portfolio momentum and diversified growth.

• FDA approvals for Cobenfy, Voranigo, and Tremfya, and acquisitions of royalties on Niktimvo, Yorvipath, and deucrictibant, strengthened the portfolio.

Financial highlights

• Q3 2024 Royalty Receipts and Portfolio Receipts both grew 15% year-over-year, reaching $735 million and $732 million, respectively.

• Adjusted EBITDA margin was approximately 92% of Portfolio Receipts; Portfolio Cash Flow margin was about 84%.

• Net income attributable to Royalty Pharma plc was $544 million, up from $72 million in Q3 2023.

• Cash and cash equivalents at quarter-end: $950 million; total debt outstanding: $7.8 billion.

• Share count reduced to 592.7 million, down 8 million from Q3 2023.

Outlook and guidance

• Full-year 2024 Portfolio Receipts guidance raised to $2.75–$2.8 billion, with Royalty Receipts growth of 11–13%.

• Milestones and other contractual receipts projected to decline from $600 million in 2023 to $30 million in 2024 due to a high base from prior accelerated payments.

• Operating and professional costs for 2024 expected at 8.5% of Portfolio Receipts; interest paid forecasted at $160 million.

• Guidance assumes no major adverse events or significant FX changes.

• Guidance excludes the impact of future royalty acquisitions and is based solely on the current portfolio.